Research on vaccines and immunization. Covers COVID and flu vaccines, outbreak response, long-lasting antibodies, and vaccination in vulnerable groups.
Researchers at Brookhaven National Laboratory have deciphered the structure of botulinum toxin, shedding light on its mechanism of action. By modifying a single amino acid, scientists created an inactive form of the toxin that retains structural similarity to the active form, paving the way for potential vaccine development.
Scientists are developing a new anthrax vaccine that requires fewer shots and has fewer side effects. The study aims to improve upon the existing vaccine, which causes numerous side effects and takes 18 months to confer protection.
A new investigational anthrax vaccine is being tested in a phase II human study at Saint Louis University. The vaccine aims to provide better protection, an improved safety profile and a simpler dosing schedule.
Drs. Thal and Nitsch receive the Potamkin Prize for their groundbreaking research on effective therapies to treat and prevent Alzheimer's disease. Their work has revitalized hopes for a vaccine and slowed cognitive decline in patients.
A survey of oncologists and nurses found that while most agree to offer trial results to patients, only 62% actually do so due to concerns over potential negative effects, patient interpretation, and resource consumption. Additionally, a new study demonstrates tamoxifen's association with reduced breast density, particularly in younger...
A study found that HIV-positive US military personnel who received a smallpox vaccine between 2002-2003 showed no negative effects. The researchers suggest exempting HIV-infected individuals from vaccination during outbreaks, but consider weakened vaccines for immunocompromised people in the future.
Researchers equipped dendritic cells with genetic material from patient's tumor and PAMPs to break T-cell tolerance, enabling activation of immune system. This approach merges strengths of viral vaccines with ease of using patient's own immune system.
A recent study examined 350 adult volunteers and found that 3.6% developed harmless skin rashes after vaccination. The rashes cleared up on their own within one to three weeks without serious symptoms.
A new dental caries vaccine is being proposed as a crucial tool to prevent the spread of tooth decay, particularly in vulnerable populations. The symposium emphasizes the vaccine's potential to combat the disease and its impact on public health.
A team of scientists has successfully tested a new smallpox vaccine that shows promise as an alternative to the existing Dryvax vaccine. The MVA vaccine was found to elicit equivalent or higher immune responses in nonhuman primates, providing protection against monkeypox.
Researchers developed a topical vaccine that induces high levels of anti-ricin immune responses in mice, with 70% survival rate upon lethal challenge. The vaccine candidate offers a viable alternative delivery route for ricin poisoning treatment.
The Phase I study demonstrated a clear dose-response relationship between the amount of rPA102 administered and the subsequent immune response, with antibody titers continuing to increase after the second and third administration. The vaccine was well-tolerated, with no evidence of dose-limiting toxicity or reactogenicity at any dose.
Researchers develop vaccine that prevents tumor growth in mice, while also reversing cardiac dysfunction through gene therapy. These breakthroughs demonstrate the potential of combinatorial approaches to vaccination and gene therapy for treating neoplastic lesions and heart disease.
A new vaccine has been shown to halt HER-2/neu preneoplastic breast cancer lesions through both morphologic and gene expression data. The findings suggest a potential breakthrough in the treatment of this type of cancer, according to a recent study published in JCI Journals.
A new vaccine has shown significant improvement in 5-year progression-free survival rates for patients with renal cancer, with a 77% rate in the vaccinated group compared to 68% in the control group. The well-tolerated treatment was associated with only 12 adverse events.
The study found that the chickenpox vaccine's effectiveness decreases significantly after one year, with 97% efficacy in the first year and 84% in subsequent years. The vaccine's effectiveness was lower for children under 15 months old, with a 73% efficacy rate.
Research by Ann Bostrom reveals that people's willingness to accept vaccine risks depends on what they do and don't know. Personal experiences with adverse reactions also impact risk perception. The study highlights the need for both technical analysis and deliberation in decision-making processes.
Dr. Offit reviews scientific evidence on vaccine safety, finding no link between vaccines and weakened immune systems, allergic or autoimmune diseases, or mercury injury. The Vaccine Education Center provides up-to-date science-based information on vaccines and preventable diseases.
A phase II trial of a melanoma vaccine showed promising results, with nearly half of patients living at least five years after receiving the treatment. The vaccine's effectiveness was influenced by the dosing schedule and immune response, highlighting the importance of personalized medicine in cancer treatment.
Dr. Peter Jahrling has been recognized by the American Association for the Advancement of Science (AAAS) as a Fellow for his contributions to vaccine development and medical defense against infectious diseases. He is credited with advancing research on filovirus and poxvirus threats.
Researchers at Purdue University developed a miniature device sensitive enough to detect a single virus particle, with applications in environmental health monitoring and homeland security. The device uses a tiny cantilever that vibrates at a specific frequency when a virus particle lands on it, allowing for real-time detection.
Researchers have successfully developed a cancer vaccine using low-affinity epitopes that shows high vaccination efficiency in antitumor immunotherapy. The study, published in JCI Journals, offers promising results for the treatment of various types of cancer.
Researchers found that a peptide called LL-37 selectively kills the vaccinia virus in the smallpox vaccine, which could enable thousands of civilians or military personnel with atopic dermatitis to receive the vaccine. This breakthrough may lead to safer testing and better predict and control reactions to the vaccine.
A new study has shown that vaccinia transfer after smallpox immunization is extremely low if proper precautions are taken. The risk of transmission can be greatly reduced by keeping the vaccine site bandaged and practicing thorough hand-washing.
A meta-analysis of five published trials found that aluminium-containing vaccines were more likely to cause redness and induration in young children and local pain in older children. However, there was no evidence of serious or long-lasting side effects.
A new recombinant tuberculosis vaccine is being tested in a Phase I clinical trial in the United States, combining two proteins known to stimulate strong immune responses in humans. The vaccine aims to offer protection against pulmonary TB, the most contagious form of the disease.
Researchers found that parents who received a photo calendar of their baby's upcoming immunization dates were more likely to vaccinate their child. The study showed an 82% vaccination rate among babies whose parents received the calendars, compared to 65% for those without.
The use of rubella vaccine has increased globally, with 124 countries using it in their immunization programs by 2002. Surveillance for congenital rubella syndrome remains a concern, with incomplete reporting and estimated cases being only 0.1% of true total.
The National Vaccine Advisory Committee recommends strengthening routine vaccine supplies by increasing funds for stockpiles, supporting regulatory agencies, and improving communication. The committee also highlights the need for increased investment in vaccine manufacturing facilities and development of new vaccines to sustain supply.
A study found that nearly 750 pediatricians and family practice physicians reported a rise in vaccine concerns, with many citing short-term effects and unproven allegations. Physicians must be equipped to address these concerns and provide accurate information on vaccine safety.
A survey of 743 physicians found that parents' refusal of vaccines is becoming a growing concern, with many citing fears about short-term reactions and long-term complications. Pediatricians are more likely than family physicians to provide additional information and discuss concerns with parents.
The meningococcal vaccine is safe and effective in preventing invasive meningococcal disease, which can cause severe illness or death. Despite its value, many parents and teens are not informed about the vaccine due to limited public resources and high costs.
The incidence of pertussis among infants increased significantly between 1980 and 1999, with a 49% rise in reported cases. The majority of these cases occurred among infants under four months old, suggesting the need for improved vaccination strategies to control the spread of the disease.
Researchers at USAMRIID have developed Ebola virus-like particles (VLPs) that induce both cell-mediated and humoral immunity in mice, providing 100% protection against lethal challenge. The VLPs, resembling infectious viral particles without genetic material, offer a promising vaccine platform for Ebola and other viruses.
A new form of coronavirus was genetically altered to resemble parts of the SARS virus, then injected into rhesus macaques. The results showed strong immune responses against SARS in all immunized animals, suggesting a potential protective vaccine.
Researchers have developed a device, known as a micromechanosensor, that allows for rapid detection of botulism toxins, which can cut detection time from days to minutes. This could lead to more effective treatment and lower mortality rates among those afflicted.
A new investigational vaccine to prevent hepatitis C has been tested in humans for the first time, offering a promising breakthrough against the deadly virus. The study aimed to assess the safety and effectiveness of three different strengths of the Chiron Corporation's vaccine.
A Phase II clinical study of TP10 found that the complement inhibitor significantly reduced heart attacks and death in male patients undergoing open heart surgery. The study showed a significant decrease in composite endpoints for death, myocardial infarction, and prolonged intubation in males treated with TP10.
Researchers have found that a new vaccine can diminish symptoms of Alzheimer's disease by increasing clearance of amyloid beta protein from the brain. The study used monkeys and showed that vaccinating them with synthetic amyloid beta peptide enhanced clearance, leading to reduced plaques and improved cognitive function.
A recent study has found a link between smallpox vaccination and rare heart diseases, including pericarditis and myocarditis. Twenty-four cases of these conditions were identified among 37,876 US civilian healthcare workers who received the vaccine as part of a bioterrorism readiness program.
Researchers found that individuals vaccinated against smallpox maintained anti-smallpox antibodies for at least 60 years after vaccination. Memory B cells initially declined but then plateaued approximately ten times lower than their peak and remained stable for over 50 years.
A UK measles expert warns that major epidemics are likely to occur in the country this winter if vaccination rates do not improve rapidly. The Lancet publication cites unequivocal evidence supporting the safety of the MMR vaccine and highlights the risks associated with unvaccinated children.
A new peptide-based vaccine has shown promising results in treating advanced melanoma by inducing a strong immune response in patients. The vaccine, which includes granulocyte macrophage-colony stimulating factor (GMCSF), resulted in significant tumor regressions and stable disease in some patients.
Researchers at the US Army Medical Research Institute of Infectious Diseases have developed a hantavirus vaccine that elicited a potent neutralizing antibody response in rhesus macaques. The vaccine, which uses a naked DNA approach, also provided protection against hamster infection when administered after exposure.
A breakthrough discovery has been made by McMaster University researchers, who have cloned the gene that marks an important nuclear protein of the SARS virus. The team plans to test their newly engineered adenovirus vector in animals for protective effects against the deadly disease.
Researchers have developed a modified smallpox vaccine that is expected to be identical in effectiveness to the current vaccine but treatable for rare complications. The new vaccine will use genes to make the virus susceptible to common drugs, allowing doctors to effectively treat severe reactions.
Hepatitis A vaccine boosters are unnecessary for healthy individuals, according to a meeting of experts; protective antibody amounts persist beyond 10 years after primary vaccination. Further investigations are needed for special patient groups.
A study by the World Health Organization found that officially reported global vaccination coverage rates are higher than actual rates, highlighting issues with data quality. The investigation compared national data with a 'gold standard' household survey method in 45 countries between 1990 and 2000.
Researchers have made significant progress towards a vaccine for pancreatic cancer, with one patient out of ten remaining disease-free after five years and two others surviving over two years. While the study's findings are promising, caution is advised due to the small sample size and potential biases in the selection process.
A new HPV vaccine targeting high-risk types could prevent up to 84% of cervical cancer cases. Testing a cocktail of these virus types could provide sufficient guidance for clinical decisions and future screening programmes.
The Emory-led consortium aims to study the entire range of human immune responses, from laboratory to clinic, to develop new vaccines addressing emerging infections and biothreats. Scientists will use genomics and proteomics to analyze vaccine-induced innate and adaptive immune responses.
Studies presented at ICAAC reveal significant clinical outcomes, resource utilization, and infection-associated costs of Staph aureus bacteremia among hemodialysis-dependent patients. The infections are associated with substantial morbidity and mortality, underscoring the need for a vaccine to prevent these infections.
The NIH has awarded $85 million to five cooperative centers for translational research on human immunology and biodefense. Researchers will develop new ways to analyze immune cells and use imaging technologies to study vaccine responses, aiming to strengthen the immune system against diseases.
Researchers at Dana-Farber and other Harvard-affiliated hospitals will study the human immune system's response to the vaccinia virus and other related viruses. The goal is to develop effective alternatives with fewer risks, addressing concerns about the current vaccine's complications in people with weakened immune systems.
Afghanistan's Ministry of Health has made significant strides in healthcare delivery and policy planning, achieving 94% national coverage in measles vaccination. The country's example is seen as a potential blueprint for post-conflict reconstruction in other nations.
A study found that organ-transplant patients are particularly vulnerable to measles due to their compromised immune systems. Low MMR vaccine uptake in southeast London poses a significant threat to these individuals, highlighting the need for increased awareness and vigilance.
A new study finds that nearly 1 in 3 doctors hesitate to administer the Prevnar vaccine due to its high cost, especially among those with many uninsured patients. The vaccine protects against bacterial meningitis and other diseases, but its expense creates obstacles for families without insurance coverage.
A new vaccine has shown promise in stimulating a powerful immune response against melanoma tumors, with 10 patients still alive three years after treatment and no signs of disease in four cases. The vaccine, made using a weakened cold virus, was safe and relatively easy to produce, with minimal side effects.
Researchers discovered that repeated vaccinations provide short-term immunity boosts but do not sustain higher protection levels. Long-term antibody immunity can last throughout a person's lifetime, while T-cell immunity declines slowly over time.
The American College of Preventive Medicine recommends prioritizing research on improving vaccine delivery and funding for immunization programs. All children and adolescents without contraindications should receive immunizations against 11 diseases, according to ACPM's recommendations.